CJC-1295 DAC (2 mg Vial) Dosage Protocol

Plan based on an 8–12 week weekly protocol.

• Peptide Vials (CJC-1295 DAC, 2 mg each):
  • 8 weeks: 8 vials (1 vial/week)
  • 12 weeks: 12 vials (1 vial/week)
• Insulin Syringes (U-100, 1 mL capacity):
  • Per week: 1 syringe
  • 8 weeks: 8 syringes
  • 12 weeks: 12 syringes
• Bacteriostatic Water (10 mL bottles): Use 1.0 mL per vial for reconstitution.
  • 8 weeks (8 vials): 8 mL — 1 bottle required (10 mL each)
  • 12 weeks (12 vials): 12 mL — 2 bottles required (10 mL each)
• Alcohol Swabs: One for the vial stopper + one for the injection site each week.
  • Per week: 2 swabs
  • 8 weeks: 16 swabs — 1 box required (100 swabs each)
  • 12 weeks: 24 swabs — 1 box required (100 swabs each)

CJC-1295 DAC 2 mg

View Supplier

U-100 syringes

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

Practice preparing this vial with the verified strength and final volume from this protocol.

• Reconstitute: Add 1.0 mL bacteriostatic water → 2.0 mg/mL (2,000 mcg/mL) concentration.
• Typical weekly dose: 2,000 mcg (2 mg) once weekly — the full vial per injection.
• Easy measuring: At 2.0 mg/mL, 1 unit = 0.01 mL = 20 mcg on a U-100 insulin syringe; full dose = 100 units (1.00 mL).
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

CJC-1295 DAC dosage protocols leverage this long-acting growth hormone-releasing hormone (GHRH) analog’s unique albumin-binding technology, which extends its half-life to approximately 6–8 days^[1][2]. By stimulating pulsatile growth hormone (GH) release while preserving natural GH rhythms, CJC-1295 DAC can elevate GH levels 2–10 fold and IGF-1 levels 1.5–3 fold in human studies^[3]. Benefits may include enhanced muscle growth and recovery, improved fat metabolism, better sleep quality, and anti-aging effects through sustained GH/IGF-1 axis activation^[4][5]. This educational protocol presents a once-weekly subcutaneous approach using a practical dilution for clear insulin-syringe measurements.

Concise summary of the once-weekly regimen.

• Goal: Elevate endogenous GH and IGF-1 levels to support muscle growth, fat metabolism, recovery, and anti-aging research^[4][5].
• Schedule: Weekly subcutaneous injections for 8–12 weeks.
• Dose: 2,000 mcg (2 mg) once weekly — one full vial per injection.
• Reconstitution: 1.0 mL per 2 mg vial (2.0 mg/mL) for accurate unit measurements.
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Suggested weekly administration approach.

• Standard Dose: 2,000 mcg (2 mg) once weekly^[7].
• Conservative Option: 1,000 mcg (1 mg) weekly if exploring lower doses.
• Frequency: Once per week (subcutaneous).
• Cycle Length: 8–12 weeks; optional 4-week break between cycles.
• Timing: Evening administration (pre-bed) may synergize with natural nocturnal GH release; rotate injection sites weekly^[6].

Proper storage preserves peptide quality and efficacy.

• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); follow product-specific use-by instructions and avoid freeze–thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each injection; dispose in a sharps container^[9].
• Rotate injection sites weekly (abdomen, thighs, upper arms) to reduce local irritation^[10].
• Inject on an empty stomach (at least 2 hours after a meal) as elevated blood sugar may blunt GH release.
• Document weekly dose, date, and site rotation to maintain consistency.

CJC-1295 DAC is a modified 30-amino-acid GHRH analog conjugated to a Drug Affinity Complex (DAC) that covalently binds to serum albumin after injection^[1]. This albumin binding dramatically extends the peptide’s half-life from minutes to approximately 6–8 days, enabling once-weekly dosing^[2]. CJC-1295 binds to GHRH receptors on pituitary somatotrope cells, amplifying GH synthesis and pulsatile release. Importantly, it elevates basal GH levels while preserving the natural rhythm of GH pulses — the frequency and amplitude remain intact^[11]. Clinical trials demonstrate sustained 2–10 fold increases in GH and 1.5–3 fold increases in IGF-1, with elevated IGF-1 persisting for up to 28 days after multiple doses^[3].

Observations from preclinical and clinical literature.

• Sustained elevation of GH and IGF-1 levels supporting muscle growth, recovery, and lean body composition^[4][5].
• Enhanced fat metabolism and potential reduction in visceral adiposity^[12].
• Improved sleep quality — GHRH analogs may have somnogenic effects, increasing deep slow-wave sleep^[6].
• Preserves natural GH pulsatility unlike exogenous GH administration^[11].
• Common side effects may include transient flushing, injection-site reactions, water retention, or headache; serious adverse effects are uncommon at standard doses^[7].

Complementary strategies for best outcomes.

• Pair with a balanced, protein-forward diet tailored to energy and recovery needs.
• Combine resistance training and aerobic activity to reinforce anabolic and metabolic adaptations.
• Prioritize sleep quality — GH is primarily secreted during slow-wave sleep^[6].
• Avoid eating 2+ hours before injection to optimize GH release response.

General subcutaneous guidance from clinical best-practice resources^[9][10].

• Clean the vial stopper and skin with alcohol; allow to dry completely.
• Pinch about an inch of skin at the injection site (lower abdomen, outer thigh, or upper arm)^[10].
• Insert the needle at a 90° angle into the pinched fold (use 45° if minimal subcutaneous fat)^[10].
• Depress the plunger fully, then withdraw the needle and dispose in a sharps container.
• Rotate sites weekly to prevent lipohypertrophy — for example, alternate between left and right abdomen^[10].

This content is for educational purposes only and is not medical advice.

• 1
  
  Journal of Clinical Endocrinology & Metabolism
  — Prolonged stimulation of GH and IGF-1 secretion by CJC-1295 in healthy adults

  View Source
• 2
  
  Clinical Pharmacology & Therapeutics
  — DAC technology: albumin-binding for extended peptide half-life

  View Source
• 3
  
  Journal of Clinical Endocrinology & Metabolism
  — Single and multiple dose pharmacokinetics of CJC-1295 in healthy subjects

  View Source
• 4
  
  Growth Hormone & IGF Research (ScienceDirect)
  — Activation of the GH/IGF-1 axis by CJC-1295 and serum protein profile changes

  View Source
• 5
  
  PubMed
  — Body composition and quality of life in adults with GH deficiency; effects of GH replacement

  View Source
• 6
  
  PubMed
  — Physiology of growth hormone secretion during sleep

  View Source
• 7
  
  Journal of Clinical Endocrinology & Metabolism
  — Safety and tolerability of CJC-1295 at various dose levels in healthy subjects

  View Source
• 9
  
  CDC
  — Preventing unsafe injection practices and clinical safety guidelines

  View Source
• 10
  
  MedlinePlus
  — Subcutaneous (SQ) injections: technique, site selection, and rotation

  View Source
• 11
  
  Endocrine Reviews
  — GHRH analogs and preservation of pulsatile GH secretion patterns

  View Source
• 12
  
  PubMed
  — Effect of tesamorelin on visceral fat in HIV-infected patients: randomized clinical trial

  View Source
• 14
  
  Pure Lab Peptides
  — CJC-1295 DAC (2 mg) product page (quality and batch documentation)

  View Source
• 13
  
  NIBSC
  — Peptide storage recommendations and stability guidelines

  View Source

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-strength variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.